A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 80
Summary
- Conditions
- Advanced Solid Tumors
- CRPC
- Genital Neoplasms, Male
- mCRPC
- Metastatic Castrate Resistant Prostate Cancer
- Neoplasms by Site
- Prostatic Neoplasms
- PT-112
- TET: Thymic Epithelia Tumors
- Urogenital Neoplasms
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase, and the Dose Expansion Phase The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase is commencing in the study of PT-112 in metastatic cas...
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase, and the Dose Expansion Phase The Dose Escalation Phase is no longer enrolling. The Dose Expansion Phase is commencing in the study of PT-112 in metastatic castrate-resistant prostate cancer (mCRPC).
Tracking Information
- NCT #
- NCT02266745
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Daniel D. Karp, MD M.D. Anderson Cancer Center
Get Well Soon